Cetuximab
monotherapy and cetuximab plus irinotecan in irinotecan-refractory
metastatic colorectal cancer
Cunningham et al.
N Engl J Med. 2004.
Phase 3, randomized, controlled, multinational, open-label, clinical
trial of cetuximab (with or without irinotecan) in patients with
epidermal growth factor receptor (EGFR)-expressing mCRC who had been
previously treated with irinotecan-based therapy.
Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal
cancer
Hurwitz et al.
N Engl J Med. 2004.
Phase 3, randomized, placebo-controlled, clinical trial of CAMPTOSAR +
bolus 5-FU/LV + bevacizumab as 1st-line treatment of patients with
metastatic carcinoma of the colon or rectum.
Randomized, controlled trial of irinotecan plus infusional, bolus,
or oral fluoropyrimidines in first-line treatment of metastatic
colorectal cancer: results from the BICC-C study
Fuchs et al.
J Clin Oncol. 2007.
Phase 3 study comparing the safety and efficacy of the following three
different irinotecan containing regimens in the first-line treatment of
metastatic colorectal cancer: irinotecan plus infusional fluorouracil
(FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and
irinotecan plus oral capecitabine (CapeIRI).
FOLFIRI followed
by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study
Tournigand et al.
J Clin Oncol. 2004.
This phase III study investigated two sequences: folinic acid, FU, and
irinotecan (FOLFIRI) followed by folinic acid, FU, and oxaliplatin
(FOLFOX6; arm A), and FOLFOX6 followed by FOLFIRI (arm B).
Strategic Planning
for Patients who Present with Metastatic Colorectal
Cancer
Benson.
Commun Oncol. 2006.
For most patients with good performance status, a treatment continuum
of cytotoxic and targeted agents over multiple therapeutic lines offers
more than palliation, and it can prolong disease-free survival and
overall survival.
View more reprints and other CAMPTOSAR-related materials in the
Clinical Library.
When you click on an item, it will open in a new window.
In order to view these PDF documents, you must have
Adobe Reader installed on your computer. If you do not have Adobe
Reader, download it from the Adobe Web site.
Note that the Adobe Web site is neither owned nor controlled by
Pfizer. Pfizer is not responsible for the content or services on that
site.
Adobe, the Adobe logo, and Reader are registered trademarks of Adobe
Systems Incorporated in the United States and/or other countries.